IPP Bureau
Ajanta Pharma - Stellar show in its branded generics: Anand Rathi
By IPP Bureau - May 12, 2022
With launches, continuing momentum in India, other branded markets and a pick-up in the US, Ajanta would deliver 12% revenue/PAT growth each over FY22-24
‘One Step’ portal to provide information on medical tourism: Dr Mansukh Mandaviya
By IPP Bureau - May 12, 2022
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Dr. Agarwal's Health Care raises over Rs 1,000 crore from TPG Growth and Temasek
By IPP Bureau - May 11, 2022
The company also raised Rs 270 crore investment from Temasek in 2019
Aurobindo Pharma Ltd gets 6 observations from USFDA for Unit VII
By IPP Bureau - May 11, 2022
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Cipla posts consolidated PAT of Rs. 362.07 crore in Q4 FY2022
By IPP Bureau - May 11, 2022
Cipla has reported consolidated financial results for the period ended March 31, 2022
Ascletis announces U.S. IND approval of ASC22 for HIV patients
By IPP Bureau - May 11, 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
Medikabazaar conducts successful trial of medical supplies through drone delivery
By IPP Bureau - May 11, 2022
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
FirstCure Health raises US $350 K in the Pre-Seed funding round
By IPP Bureau - May 11, 2022
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Alembic Pharmaceuticals receives USFDA approval for Arformoterol Tartrate
By IPP Bureau - May 11, 2022
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
Dr. Reddy's to commercialise Tegoprazan in India and six emerging markets
By IPP Bureau - May 11, 2022
HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Hetero unveils new logo and corporate brand identity
By IPP Bureau - May 11, 2022
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
DSM, UNICEF and Sight and Life extend global partnership to address malnutrition
By IPP Bureau - May 11, 2022
The partners also aim to expand their work to Latin America for the first time
New nirsevimab data analyses reinforce efficacy against RSV
By IPP Bureau - May 11, 2022
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
Bayer posts higher sales, profit in first quarter
By IPP Bureau - May 11, 2022
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
Aarti Drugs Q4FY 22 consolidated revenue grew by 39 per cent YoY
By IPP Bureau - May 10, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
